Intelligent Bio Solutions expands global reach with Drug Screening System upgrade

Intelligent Bio Solutions Inc., a leading medical technology company specializing in rapid, non-invasive testing solutions, has announced a significant upgrade to its Intelligent Fingerprinting Drug Screening System. This strategic enhancement introduces multilingual support, making the system accessible to over 4 billion people worldwide, spanning languages spoken across North and South America, Europe, Asia Pacific, and the Middle East.

The integration of multilingual capabilities into the portable Drug Screening Reader marks a pivotal advancement in INBS’ commitment to global accessibility. This upgrade is designed to meet the diverse linguistic needs of multinational organizations operating in complex, multilingual environments. By facilitating broader usability, INBS aims to improve operational efficiency and ensure seamless drug screening processes across safety-critical industries such as construction, mining, manufacturing, transport, and logistics.

The global workplace drug testing market is experiencing rapid growth, projected to reach approximately $8 billion by 2030. INBS' multilingual upgrade positions the company to capture a significant share of this expanding market by offering user-friendly solutions that cater to a diverse workforce. This development underscores the company's proactive approach to addressing emerging trends and regulatory requirements in workplace safety and compliance.

Harry Simeonidis, President & CEO of Intelligent Bio Solutions, highlighted the strategic importance of this upgrade, stating, "As we expand our global footprint, it is essential that our solutions are accessible and adaptable to meet the needs of an increasingly diverse customer base. This multilingual upgrade to our drug screening reader represents a significant step forward in our mission to deliver accessible testing solutions. Importantly, this update will open up opportunities for us to enter new international markets and customer segments, supporting revenue growth."

INBS’ innovative Intelligent Fingerprinting Drug Testing Solution leverages advanced fingerprint sweat analysis technology to detect multiple substances of abuse simultaneously, providing a non-invasive, efficient, and reliable alternative to traditional drug testing methods. The introduction of multilingual support aligns with INBS’ broader strategic goals, including its recent FDA 510(k) submission in December 2024, established presence in 19 countries, and anticipated entry into the U.S. market in 2025.

This upgrade not only enhances the user experience but also reinforces INBS' dedication to advancing global health and safety standards through intelligent, adaptable, and cutting-edge medical technologies.